Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRP-Based Early Intervention for Home Quarantined COVID-19
NCT04935515Completed
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of azithromycin, methylprednisolone injection, rivaroxaban, ceftriaxone and dexamethasone in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoint: Number of home quarantined COVID-19 positive patients requiring admission in a hospital for hypoxia at 2 weeks. Started Apr 2021; status: completed.
02
Drugs
azithromycinmethylprednisolone injectionrivaroxabanceftriaxonedexamethasone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04935515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935515.